The Interaction of Podocytes, Glomerular Cells and Mesangial Cells in Glomerulopathies

Abbreviations: AKI: Acute Kidney Injury; ESRD: End-Stage Renal Disease; CKD: Chronic Kidney Disease; Cd2ap: CD2-AssZociated Protein; JAK2: Janus kinase 2; USP40: carboxyl Terminal Hydrolase 40; UCHL1: Carboxyl Terminal Hydrolase L1; MMP: 2.4.1. Matrix Metalloproteinases; ECM: Extracellular Matrix; MMP-9: Metallopeptidase 9


Introduction
Glomerular disease is the collective term to designate diseases that affect the structure and function of the glomerulus [1]. The causes of this entity are divided into primary or secondary.
Generally, it is not an easy task to differentiate them because of their various forms of presentation, which vary in severity from asymptomatic urinary abnormalities to acute kidney injury (AKI) or end-stage renal disease (ESRD) [2] Primary glomerulopathies refer to those entities in which renal involvement is not the consequence of a more general disease and the clinical manifestations are System" [6]. Taking into account only the primary glomerulopathies in the pediatric population generate 5%-14% of children with chronic kidney disease and 15%-29% of children with end-stage renal disease [7] Consequently, it is a pathology that contributes to the genesis of CKD, which in turn generates morbidity, mortality and annually high costs to the health system in many countries of the world. For all the above, glomerulopathies have historically had a special place in the medical community, especially in nephrologists, which is why these communities have been interested in understanding the pathophysiological mechanisms of glomerulopathies. Years ago, the management of this pathology was classified by the scientific community as "ordinary and inelegant" because steroids, cyclophosphamide, among other therapies were being used in little-known terrain. However, in recent years, knowledge of the pathophysiology of glomerular diseases has advanced rapidly. One of the topics that the medical community has emphasized is the role of important cells such as podocytes, mesangial cells and glomerular endothelial cells in glomerulopathies, which will be the objective of this article. See Figure 1 However, before focusing on the aforementioned topic, it is pertinent to mention the physiological role they play at the renal level [8].

a) Glomerular Structure
Within the nephron, the glomerular filtration barrier is responsible for the selective filtration of blood from the afferent arteriole to Bowman's space. The filtration barrier includes 3 layers: glomerular epithelium, the basement membrane, and the slit diaphragms, which are made up of podocytes. The slit diaphragm is the final barrier that prevents the passage of proteins to the urinary filtrate. The filtrate that passes into Bowman's space continues into the proximal tubule and loop of Henle for further processing [9].

b) Podocytes
In recent years we have witnessed novel advances in optical and electron microscopy techniques in the biomedical sciences.
This has helped better understanding in multiple fields of medicine, a clear example is podocytes. These cells reside as specialized pericytes that cover the glomerular capillary endothelial cells into the parietal epithelial cells lining Bowman's capsule. Together with the capillary endothelial cells, the podocytes form the glomerular basement membrane, which appears to be the decisive filtration layer in controlling the glomerular filtration barrier [11][12][13]. For decades, these cells have been related, given their importance in the glomerulus, with glomerulopathies, especially in nephrotic syndrome, focal and segmental glomerulosclerosis, diabetic and hypertensive nephropathy, where it has been found that the lesion and / or decrease in the number of these, sit contributes to the genesis of these pathologies [14][15][16]. As podocytes decrease in number, the glomerular filtration barrier is affected. In addition, the low capacity of these cells to regenerate makes them very prone to damage. In an experimental study carried out by Bryan L. Wharram, it was found that after 20% of the damage of these cells there was a higher proportion of glomeruli containing synechiae and segmental areas of podocyte depletion and glomerulosclerosis [17]. Multiple theories have been proposed on the mechanisms of injury and / or reduction of podocytes. However, the objective of this article is to review the mechanisms that have had greater progress in the scientific community in recent years and their relationship with glomerulopathies, among which we find:

c) Role of Podocyte Proteases
Proteolysis is an important mechanism that influences physiological and pathophysiological processes, such as differentiation, development, apoptosis, and cancer. In the case of podocytes, they play a prominent role in the degradation of proteins important to their architecture. Extracellular and intracellular proteases have been studied.

Intracellular Proteases
Cathepsins: Within the intracellular proteases we find this group. The first one related was cathepsin L, an intracellular cysteine protease, which has been related to multiple pathological glomerular states. For example, in the study carried out by Garsen M et al in relation to diabetic nephropathy [18,19]. Captesin L is believed to promote proteolysis of CD2-associated protein (Cd2ap) and synaptopodin. Furthermore, it leads to dynamic cleavage at an evolutionarily conserved site, resulting in reorganization of the podocyte actin cytoskeleton [20,21]. Other type of cathepsin that has been linked to glomerular pathologies is cathepsin D, it is an aspartic protease, which is important to maintain the integrity of podocytes, since mice deficient in cathepsin D develop cleavage diaphragm fragmentation, proteinuria and end-stage renal disease. [19,22]. Given the previously described findings, a study was The study result did not reduce blood pressure or other aspects of glomerular injury that were induced by salt-sensitive hypertension [23]. Another study carried out by Tamadher A Alghamdi found that by inhibiting Janus kinase 2 (JAK2), in addition to other effects, it led to a down regulation in the expression of lysosomal genes and a decreased activity of the lysosomal enzyme, cathepsin D, generating thus reversal of lysosomal dysfunction and restoration of albumin selectivity permeability [24]. Calpain: a calcium-dependent cysteine protease, it was originally identified as a protease that cleaved talin, an important focal adhesion molecule in the podocyte [19,31]. As a result, studies have shown evidence of an improvement of renal function in focal and segmental glomerulosclerosis. Therefore, the inhibition of this protease has been proposed as a possible future therapeutic target in the management of focal and segmental glomerulosclerosis [32.33].
Caspases: These proteases belong to a family of highly conserved aspartate-specific cysteine proteases and are members of the family of interleukin-1 beta converting enzymes, present in multicellular organisms. By Wang Y et al. [34,35] the role of protease-activated receptor 2 in the regulation of focal and segmental glomerulosclerosis was studied; the research group concluded that this receptor plays an important role in mediating injury. Kidney disease induced by glomerulosclerosis and even its inhibition has a protective effect at the renal level [35].

Extracellular Proteases
Matrix Metalloproteinases (MMP): proteins that are part of the extracellular matrix (ECM) which are capable, in their environment, of activating growth factors, surface receptors and adhesion molecules. In addition, they affect the degradation and exchange of the extracellular matrix protein, due to its action glomerular pathologies have been investigated [36,37]. In the study by Szu-Yuan Li, the relationship of metallopeptidase 9 (MMP-9) and diabetic nephropathy was studied. It was found to appear to play a role in the development of diabetic nephropathy.
Likewise, it disrupted the integrity of podocyte cells, promoted the permeability of the podocyte monolayer to albumin, and the synthesis of extracellular matrix proteins [37].
Thrombin: it is a serine protease that interacts with receptors activated by protease (PAR). PARs are expressed throughout the body; At the renal level, G protein-coupled receptors have been found in mesangial cells and podocytes [38]. Likewise, elevated urinary thrombin is associated with glomerulonephritis and leads to overstimulation of PAR, increased intracellular calcium levels, proteinuria, and deterioration of the glomerulus [19]. Based on the findings described above, a study was conducted by Yu Guan et al in where they suggested that PAR-1 antagonists have therapeutic potential [35].
Oxidative Stress: Reactive oxygen species (ROS) are free radicals derived from oxygen, which are unstable chemicals and attack cell proteins and lipids, leading to cell dysfunction [39].
They play a crucial role in physiological processes and human pathophysiology; glomerular pathologies have not been the exception. These reactive oxygen species have been found to contribute to podocyte injury by different mechanisms, among them we find the study by Katalin Susztak et al in which podocyte apoptosis increased sharply with the appearance of hyperglycemia in mice due to the generation of ROS [40].

Role of Mitochondria
Mitochondria are essential organelles that meet the energy requirements of the cell through the generation of adenosine triphosphate (ATP). The kidney has the second highest density of mitochondria which helps meet the energy requirement to carry out essential functions, including blood filtration to remove waste, reabsorption of nutrients, maintenance of electrolyte and fluid homeostasis, secretion of hormones and blood pressure regulation [41]. Mitochondrial dysfunction leads to decreased ATP production, alterations in cell structure and functions, and loss of kidney function. When this is persistent, it plays a role in the early stages and progression of kidney diseases, such as acute kidney injury (AKI) and diabetic nephropathy, as it alters mitochondrial homeostasis and, therefore, normal kidney function [42]. This mechanism has been proposed because recent studies revealed that dysfunction of energy transduction in podocytes may be the basis of podocyte injury associated with numerous glomerular diseases, since these are very dynamic cells and require high energy to maintain the organization of the proteins of the cytoskeletal and extracellular matrix, its motility and remodeling, and their low capacity to regenerate makes them very prone to injury [41]. It was concluded in a study by Yoshifusa Abe that mitochondria play the main role in maintaining podocyte energy homeostasis. [43] Similarly, there are agents that coordinate the general regulation of biological programs at the mitochondrial level and play a fundamental role in podocyte energy homeostasis. These are peroxisome proliferator-activated receptors and peroxisome proliferator-activated receptor 1α (PGC-1α) coactivator. The balance in mitochondrial biogenesis promoted by PGC-1α is believed to be critical to maintaining podocyte health.
However, the increase in mitochondrial fusion by Dynamin-1 like protein (DNM1L) has a detrimental effect on podocytes under cellular stress, in this subject there are still many questions to answer which are still under study [41].

Glomerular Endothelial cells
Glomerular endothelial cells are characterized by fenestrations, circular transcellular pores 60-80 nm in diameter, essential for water permeability. The presence of fenestrations has meant that the glomerular endothelium contributes little to the macromolecular barrier. However, it is now widely accepted that the luminal surface of the glomerular endothelium is covered with a glycocalyx that constitutes a significant permeability barrier [44].
It has been found in certain pathologies, where endothelial injury leads to altered microvascular permeability and albuminuria [45].
Within pathologies in which the lesion of these cells is typical, we find rapidly progressive glomerulonephritis including ANCAassociated GN, anti-GBM GN, and class 3 and 4 lupus nephritis.
Entities in which the decrease in the glomerular filtration rate is accompanied by a loss of the fenestral area. Among these we find preeclampsia observed in a study carried out by RA Lafayette et al. [46] and diabetic nephropathy observed in a study carried out by Masao Toyoda et al. [47].
It is believed that the mechanism by which diabetes affects endothelial cells is through endothelial dysfunction mediated by glucose and its by-products, generating an alteration of the glomerular filtration barrier by increasing the permeability of endothelial cells. glomerular cells, leading to the induction of endothelial cell apoptosis. Concomitantly, they impair endothelial repair capacity by reducing the number and function of endothelial progenitor cells [45][46][47][48]. Another of the related pathologies are those mediated by complement, within these we have the previously called atypical hemolytic uremic syndrome, currently called complement-mediated thrombotic microangiopathy [49]. It has even been found that certain inflammatory stimuli such as histamine, thrombin, vascular endothelial growth factor, and activated neutrophils can cause dissociation of cell-cell junctions between endothelial cells, as well as contraction of the cytoskeleton, leading to an expanded intercellular space that facilitates transendothelial flow [50] Another of the components in which it contributes significantly to the glomerular filtration barrier is the endothelial glycocalyx.
This dysfunction has been found to be related to the appearance of albuminuria and increased microvascular permeability [51,52] Diabetic nephropathy through the persistent hyperglycemia mechanism has been related to glycocalyx dysfunction and this in turn leads to the appearance of proteinuria in diabetics. In a study by Un Singh et al., The effects of high glucose on the biochemical structure of the glycocalyx were studied, where its damage was corroborated [53] Another mechanism of injury to the endothelial glycocalyx is through the generation of reactive species oxygen, a study by Anurag Singh confirmed his premise [54]. Given these findings, the scientific community has studied possible therapeutic targets that improve dysfunction at the level of these two cellular structures, especially in diabetic nephropathy. They find a group in which they act indirectly. Among these we find the new antidiabetic therapies, which have recently shown a specific benefit in diabetic nephropathy, probably because it involves the protection of the renal endothelium [48]. Studies have been carried out in the group that act in a specific way. A study carried out by Raina D Ramnath formed in or delivered to glomerular capillaries [58,59]. There is increasing evidence to support the role of glomerular mesangial cell proliferation and overproduction of extracellular matrix by mesangial cells in the development of glomerulopathies [60]. It was found that the B subunit of platelet-derived growth factor, which is a potent mitogen in these cells, is positively regulated in glomerular pathologies such as IgA nephropathy, diabetic nephropathy, lupus nephritis, among others [61,62]. This leads to the expansion of the mesangial matrix and the release of vasoactive mediators, thus resulting in a decrease in the glomerular surface area and an alteration in glomerular hemodynamics, with a decrease in GFR. If this persists, it leads to interstitial fibrosis, followed by glomerulosclerosis [45,63]. Another way in which these cells are related to glomerular pathologies is by serving as a deposit target.
An example of this is the deposition of IgA in diabetic nephropathy.
Another pathology in which accumulation at the mesangial level is evidenced is in lupus nephropathy [45,64]. Another pathology related to these cells is alport disease. In the study by Brianna Dufek et al, supported by the theory that this glomerulopathy is mediated by strain-sensitive biomechanical activation of mesangial actin dynamics. In this study, it was found that the activation of the endothelin A receptor in mesangial cells is a key event in the onset of the disease [65]. Through animal experiments, these cells have been studied as a possible therapeutic target. Among the therapeutic targets there are 3 that have been the most studied:  [68] Likewise, this inhibitor showed a decrease in proteinuria, an improvement in creatinine clearance and a decrease in glomerular cell proliferation [67,68]. Another finding was in conventional treatments such as corticosteroids, it was evidenced that their beneficial effect in glomerular pathologies has been through the inhibition of NFκB [69].

Platelet-Derived Growth Factor (PDGF):
It is a potent mitogen and a key survival factor for mesangial cells [67] In a study by C Zoja et al. [70] imatinib, a PDGF receptor tyrosine kinase inhibitor, was found to improve animal survival and renal manifestations in lupus mice. They also suggest the possibility of exploring whether Imatinib in the management of human lupus nephritis in the context of a steroid-sparing drug in human lupus nephritis [70].
Transforming Growth Factor beta: TGF-β is the prototype of the TGF-β family of growth and differentiation factors. It is encoded by 33 genes in mammals and comprises homo and heterodimers [71]. Binding of TGFβ to its receptor has been found to lead to phosphorylation of Smad2 and Smad3, this in turn translocates to the nucleus with Smad4 and upregulates collagen alpha transcription leading to increased collagen synthesis. Concomitantly, they lead to the phosphorylation of the early growth response protein 1 (Egr-1), through casein kinase 2 [67,72]. A study was carried out by Hirotaka Fukasawa, in which he showed that TGF-B causes an increase in the synthesis of mesangial cells, mesangial proliferation and glomerular fibrosis. Furthermore, in the same study an anti-TGF-β antibody was used resulting in amelioration of chronic progressive nephritis by inhibiting Smad / TGF-β signaling [67,73] Indirectly there is also evidence, the study carried out by Bernd Hohenstein et al., Used vardenafil, a specific inhibitor of the specific inhibition of phosphodiesterase type 5. It is known that it in turn activates TGF-B, thus finding the beneficial antiproliferative and antifibrotic effect in proliferative mesangial glomerulonephritis [74].

Conclusion
Glomerular diseases manifest as various clinical syndromes and etiologies that are not clearly understood. Glomerular changes are complex and affect all types of glomerular cells, including podocytes, glomerular endothelial cells, and mesangial cells. Understanding the role of each of these cells in glomerular pathologies helps the scientific community to have new therapeutic targets. Targeted therapies have been shown to reduce drug dosage and therefore minimize side effects. This is especially attractive in chronic kidney diseases that require treatment for long periods and could contribute in the future to reduce morbidities and mortality in the terminal stage of many glomerupathies such as CKD.